Prohibitin as a novel target protein of luteinizing hormone in ovarian epithelial carcinogenesis

Neoplasma

Volumn 58, Issue 2, 2011, Pages 104-109

  Jia, L ^a,e   Yi, X F ^b   Zhang, Z B ^c   Zhuang, Z P ^d   Li, J ^d   Chambers, S K ^d   Kong, B H ^e   Zheng, W ^a,e,f  

^a SHANDONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Gonadotropin; Luteinizing hormone; Ovarian cancer; Prohibitin

Indexed keywords

GONADOTROPIN; LUTEINIZING HORMONE; PROHIBITIN; REPRESSOR PROTEIN;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CYSTADENOMA; FEMALE; HUMAN; HUMAN TISSUE; OVARY TUMOR; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN TARGETING; PROTEOMICS; AMINO ACID SEQUENCE; CHEMISTRY; IMMUNOHISTOCHEMISTRY; MOLECULAR GENETICS; NEOPLASM; OVARY; PHYSIOLOGY; TUMOR CELL LINE;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUTEINIZING HORMONE; MOLECULAR SEQUENCE DATA; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; PROTEOMICS; REPRESSOR PROTEINS;

EID: 79961156167     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_02_104     Document Type: Article

References (30)

1. SCULLY RE. Pathology of ovarian cancer precursors. J Cell Biochem Suppl 1995; 23, 208-218. doi:10.1002/jcb.240590928
2. SHIH IE M, KURMAN RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164, 1511-1518.
3. BISKIND MS, BISKIND GR. Development of tumors in the rat ovary after transplantation into the spleen. Proc Soc Exp Biol Med 1944; 55, 176-179.
4. CRAMER DW, WELCH WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983; 71, 717-721.
5. WHITTEMORE AS, HARRIS R, ITNYRE J, HALPERN J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. I. Methods. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136, 1175-1183.
6. LA VECCHIA C, FRANCESCHI S. Oral contraceptives and ovarian cancer. Eur J Cancer Prev 1999; 8, 297-304. misctextdoi:10.1097/00008469-199908000-00005/misctext
7. DUBEAU L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol 1999; 72, 437-442. doi:10.1006/ gyno.1998.5275
8. CRUM CP, DRAPKIN R, MIRON A, INCE TA, MUTO M et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007; 19, 3-9. misctextdoi:10.1097/GCO.0b013e328011a21f/misctext
9. LU JJ, ZHENG Y, KANG X, YUAN JM, LAUCHLAN SC et al. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. Gynecol Oncol 2000; 79, 158-168. doi:10.1006/gyno.2000.5928
10. OKAMOTO H, LI J, VORTMEYER AO, JAFFE H, LEE YS et al. Comparative proteomic profiles of meningioma subtypes. Cancer Res 2006; 66, 10199-10204. doi:10.1158/0008-5472. CAN-06-0955
11. FURUTA M, WEIL RJ, VORTMEYER AO, HUANG S, LEI J et al. Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene 2004; 23, 6806-6814. misctextdoi:10.1038/sj.onc.1207770/misctext
12. BENEDET JL, BENDER H, JONES H, 3rd, NGAN HY, PECORELLI S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000; 70, 209-262. doi:10.1016/S0020-7292(00)90001-8
13. THOMPSON WE, POWELL JM, WHITTAKER JA, SRI-DARAN R, THOMAS KH. Immunolocalization and expression of prohibitin, a mitochondrial associated protein within the rat ovaries. Anat Rec 1999; 256, 40-48. doi:10.1002/(SICI)1097-0185(19990901)256:1<40::AID-AR6>3.0.CO;2-X
14. MISHRA S, MURPHY LC, NYOMBA BL, MURPHY LJ. Prohibitin: a potential target for new therapeutics. Trends Mol Med 2005; 11, 192-197. doi:10.1016/j.molmed.2005.02.004
15. NUELL MJ, STEWART DA, WALKER L, FRIEDMAN V, WOOD CM et al. Prohibitin, an evolutionarily conserved intracellular protein that blocks DNA synthesis in normal fibroblasts and HeLa cells. Mol Cell Biol 1991; 11, 1372-1381.
16. GUO W, XU H, CHEN J, YANG Y, JIN JW et al. Prohibitin suppresses renal interstitial fibroblasts proliferation and phenotypic change induced by transforming growth factor-beta1. Mol Cell Biochem 2007; 295, 167-177. doi:10.1007/s11010-006-9286-4
17. GAMBLE SC, ODONTIADIS M, WAXMAN J, WESTBROOK JA, DUNN MJ et al. Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene 2004; 23, 2996-3004. doi:10.1038/sj.onc.1207444
18. REN HZ, WANG JS, WANG P, PAN GQ, WEN JF et al. Increased Expression of Prohibitin and its Relationship with Poor Prognosis in Esophageal Squamous Cell Carcinoma. Pathol Oncol Res 2010; Jan 13.
19. WANG S, FUSARO G, PADMANABHAN J, CHELLAPPAN SP. Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression. Oncogene 2002; 21, 8388-8396. doi:10.1038/sj.onc.1205944
20. FUSARO G, DASGUPTA P, RASTOGI S, JOSHI B, CHELLAPPAN S. Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem 2003; 278, 47853-47861. doi:10.1074/jbc.M305171200
21. JUPE ER, LIU XT, KIEHLBAUCH JL, MCCLUNG JK, DELLORCO RT. The 3'untranslated region of prohibitin and cellular immortalization. Exp Cell Res 1996; 224, 128-135. misctextdoi:10.1006/excr.1996.0120/misctext
22. MANJESHWAR S, BRANAM DE, LERNER MR, BRACK-ETT DJ, JUPE ER. Tumor suppression by the prohibitin gene 3'untranslated region RNA in human breast cancer. Cancer Res 2003; 63, 5251-5256.
23. SIEVERS C, BILLIG G, GOTTSCHALK K, RUDEL T. Prohibitins are required for cancer cell proliferation and adhesion. PLoS One 5, e12735. doi:10.1371/journal.pone.0012735
24. THOMPSON WE, ASSELIN E, BRANCH A, STILES JK, SUTOVSKY P et al. Regulation of prohibitin expression during follicular development and atresia in the mammalian ovary. Biol Reprod 2004; 71, 282-290. doi:10.1095/biolreprod.103.024125
25. GREGORY-BASS RC, OLATINWO M, XU W, MATTHEWS R, STILES JK et al. Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis. Int J Cancer 2008; 122, 1923-1930. doi:10.1002/ijc.23351
26. PENG X, MARUO T, MATSUO H, TAKEKIDA S, DEGUCHI J. Serum deprivation-induced apoptosis in cultured porcine granulosa cells is characterized by increased expression of p53 protein, Fas antigen and Fas ligand and by decreased expression of PCNA. Endocr J 1998; 45, 247-253. doi:10.1507/endocrj.45.247
27. RISCH HA, MARRETT LD, JAIN M, HOWE GR. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 1996; 144, 363-372.
28. SYED V, ULINSKI G, MOK SC, HO SM. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J Natl Cancer Inst 2002; 94, 617-629.
29. IVARSSON K, SUNDFELDT K, BRANNSTROM M, HELLBERG P, JANSON PO. Diverse effects of FSH and LH on proliferation of human ovarian surface epithelial cells. Hum Reprod 2001; 16, 18-23. doi:10.1093/humrep/16.1.18
30. ZHENG W, LU JJ, LUO F, ZHENG Y, FENG Y et al. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 2000; 76, 80-88. doi:10.1006/gyno.1999.5628